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Abstract
Background: Diabetes and TB are associated, and diabetes is increasingly common in low-income countries where
tuberculosis (TB) is highly endemic. However, the role of diabetes for TB has not been assessed in populations where HIV is
prevalent.
Methods: A case-control study was conducted in an urban population in Tanzania among culture-confirmed pulmonary TB
patients and non-TB neighbourhood controls. Participants were tested for diabetes according to WHO guidelines and serum
concentrations of acute phase reactants were measured. The association between diabetes and TB, and the role of HIV as an
effect modifier, were examined using logistic regression. Since blood glucose levels increase during the acute phase
response, we adjusted for elevated serum acute phase reactants.
Results: Among 803 cases and 350 controls the mean (SD) age was 34.8 (11.9) and 33.8 (12.0) years, and the prevalence of
diabetes was 16.7% (95% CI: 14.2; 19.4) and 9.4% (6.6; 13.0), respectively. Diabetes was associated with TB (OR 2.2, 95% CI:
1.5; 3.4, p,0.001). However, the association depended on HIV status (interaction, p = 0.01) due to a stronger association
among HIV uninfected (OR 4.2, 95% CI: 1.5; 11.6, p = 0.01) compared to HIV infected (OR 0.1, 95% CI: 0.01; 1.8, p = 0.13) after
adjusting for age, sex, demographic factors and elevated serum acute phase reactants.
Conclusion: Diabetes is a risk factor for TB in HIV uninfected, whereas the association in HIV infected patients needs further
study. The increasing diabetes prevalence may be a threat to TB control.
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Introduction
The number of people living with type 2 diabetes mellitus
(diabetes) is projected to double between 2000 and 2030, based on
increasing life-expectancy and urbanization [1]. Furthermore, the
incidence of diabetes seems to continue to increase [2,3], due to
continuing changes in life-style [4,5].
There is evidence to suggest that diabetes increases the risk of
lower respiratory tract and other infections [6–8]. The mecha-
nisms are not clear, but may be through impaired cell-mediated
immunity [3] as well as neutrophil function [9–11]. Such effects
are likely to be particularly detrimental in low-income countries,
where diabetes usually remains undiagnosed or untreated due to
weak health systems [12], and may occur in individuals with high
exposure to tuberculosis (TB) and other infectious diseases.
More than 9 million people are diagnosed with TB each year,
with HIV infection and undernutrition as well-established risk
factors [13]. Studies primarily from middle and high-income
countries suggest that diabetes is in fact associated with increased
risk of TB. However, any effect of diabetes on risk of TB and other
infections is of greater concern in low-income countries. If indeed
diabetes is a risk factor for primary infection with TB or
progression from latent TB infection to active TB disease, then
increasing diabetes prevalence in TB endemic areas will further
increase the TB burden. Yet, in high TB burden countries little is
known about the prevalence of diabetes, and, as recently reviewed
[14], no studies on the role of diabetes for TB have been carried
out in Africa. Hence, the effect of diabetes on risk of TB has not
been assessed in a population with a high prevalence of HIV, a
known strong competing risk factor.
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With more than 70.000 new cases each year Tanzania is one of
the world’s 22 high TB-burden countries [15]; one half of the TB
cases are co-infected with HIV [16]. As of 2009, the estimated
HIV prevalence in Tanzania is 5% [17]. We conducted a case-
control study in Mwanza, Tanzania, to assess the association
between diabetes and pulmonary TB, while assessing the role of
HIV as a potential effect modifier.
Methods
Ethics statement
Ethical permission was obtained from the Medical Research
Coordinating committee of the National Institute for Medical
Research (NIMR) in Tanzania. Study approval was given by The
Danish Central Medical Ethics Committee. Written and oral
information was presented to all eligible participants by the health
staff before written informed consent was obtained. Written
consent was obtained from parents/legal guardians of any
participants under 18 years of age.
Subjects and study design
The study was conducted from April 2006 to January 2009 in
Mwanza, Tanzania. Mwanza city has approximately half a million
inhabitants, and is located on the southern shores of Lake Victoria.
The city is administratively divided into 21 wards, 208 sub-wards
and about 500 streets. Each street is further divided into an
informal communal cell with 10–20 households (ten-cell), headed
by a ten-cell leader. As part of a nutrition study, patients newly
diagnosed with pulmonary TB at four major health facilities in
Mwanza city were invited to participate in the study. Patients
below 15 years of age, pregnant or lactating women, patients
terminally ill from TB or HIV (judged unlikely to survive
.48 hours), patients suffering from other severe diseases, and
non-residents of Mwanza City were excluded. TB patients were
diagnosed and treated according to international guidelines [18].
Among 866 microscopically confirmed pulmonary TB patients
enrolled in the nutritional study [19,20], we invited 400
consecutive patients to participate as index cases in the case-
control study. Controls were recruited consecutively during a
limited time. During the recruitment of controls all TB patients
were invited as an index case. Index cases consenting to participate
in the case-control study were asked to provide detailed contact
information about address and their ten-cell leader. In co-
operation with the ten-cell leader a complete list of individuals
from the same ten-cell, with the same sex, and similar age (+/- 5
years) as the case was made. From the list of potential controls one
individual was then randomly selected using a lottery method, and
invited to participate. The same inclusion and exclusion criteria
used for cases were applied to controls, except that history of TB in
the household of the participant as well as evidence of active TB
(cough, intermittent fevers, excessive night sweating in the past two
weeks, and unexplained weight loss in the past month) were
exclusion criteria among controls. If the invited control was not
eligible, then another was randomly selected. Both index and non-
index cases were included as cases.
Measurements
Pulmonary TB cases were initially diagnosed with sputum-
positive pulmonary TB using microscopy based on the three
sputum samples submission procedure (‘‘spot-morning-spot’’)
collected at the local health facility. An additional early morning
sputum sample was collected in a sterile universal bottle, and
culture of Mycobacterium tuberculosis was done on Lowenstein Jensen
solid media at the Zonal TB Reference Laboratory. Except for TB
diagnostics, cases and controls underwent the same examinations,
and the same demographic and medical history information was
collected using standardised questionnaires.
Venous blood was drawn and serum collected and kept at
280uC until analysis. HIV status was determined using two rapid
tests, Determine HIV 1/2 (Inverness Medical Innovations Inc.,
Delaware, USA) and Capillus HIV-1/HIV-2 (Trinity Biotech Plc.,
Wicklow, Ireland). If the tests were equivocal, HIV diagnosis was
based on ELISA. Serum concentrations of the acute phase
reactants, C-reactive protein (CRP) and alpha-1-acid glycoprotein
(AGP) were determined at the Department of Clinical Biochem-
istry, Aalborg University Hospital, Denmark. Serum CRP was
reported in mg/L and serum AGP in g/L with a lowest detection
limit at 10 mg/L and 0.4 g/L, respectively. Serum CRP above
10 mg/L and AGP above 1.2 g/L were reported as elevated
[21,22]. Weight and height were measured with the participant
barefooted and with minimal clothing to the nearest 0.1 kg and
0.1 cm, respectively. The body mass index (BMI) was calculated as
weight/height2 (kg/m2).
Cases and controls were tested for impaired glycaemia and
diabetes and diagnosed according to the most recent WHO
classification [23]. The testing was performed a few days after the
initiation of TB treatment, since the patients were not fasting on
the day of recruitment. The diagnosis was based on fasting
capillary blood glucose (FBG) and 2 hour blood glucose (2hBG)
after a standard 75 g oral glucose tolerance test (OGTT). Blood
glucose levels were analysed using the HemoCue Glucose System
(HemoCue, A¨ngelholm, Sweden). Measurement of FBG and the
OGTT procedure were performed in the morning. All partici-
pants were instructed to fast from midnight (.8 hours). They were
only allowed to take water prior to the test. The OGTT was
performed on participants with a FBG between 5.1–11.0 mmol/L.
Patients with FBG values below 5.1 mmol/L were categorized as
having normal glycaemia, and those with values above 11 mmol/
L as having diabetes. Based on FBG and 2hBG post OGTT, the
participants could further be categorized with isolated impaired
fasting glucose (iIFG), isolated impaired glucose tolerance (iIGT),
combined IFG/IGT or diabetes [24]. Final diabetes diagnosis was
based on either a FBG.6 mmol/L or a 2hBG.11 mmol/L [23].
Participants diagnosed with diabetes were referred to the local
diabetes clinic for management. In the present study, all
participants were tested irrespective of prior diabetes diagnosis
and only classified as having diabetes if the diagnosis could be
confirmed by the study [23].
Statistical analysis
Data were double entered, and all statistical analyses were
performed using Stata 11.0 (Stata Corp., Texas, USA). Only cases
and controls with complete data on glucose tolerance status were
included in the analysis. Cases were only included if the sputum
culture confirmed the TB diagnosis, unless culture was missing or
contaminated, in which case diagnosis was based on a sputum
positive microscopy. P-values ,0.05 were considered significant.
Blood glucose levels were analysed as continuous variables to
estimate the association between blood glucose levels (FBG and
2hBG) and TB. Finally, glucose tolerance status was defined as
normal glycaemia (reference group), iIFG, iIGT, combined IFG/
IGT, and diabetes. Logistic regression was used to estimate the
role of impaired glycaemia and diabetes as a risk factor for TB;
also stratified by HIV status. In the logistic regression adjusted for
age, sex, socio-demography, HIV and AGP we combined iIFG,
iIGT and combined IFG/IGT (IFG/IGT). Due to a TB-related
weight deficit of 9–10 kg [24], BMI and waist circumference
would have functioned as nearly full proxy variables for case status
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in this study sample, and were consequently not included in the
final analysis.
Results
Of the 866 TB cases and 355 controls recruited, 803 (93%) and
350 (96%) had complete blood glucose data and thus included in
the case-control analysis. Among TB cases 735 (92%) were
culture-positive and 68 were diagnosed as sputum positive using
smear microscopy due to either a contaminated or missing culture
sample. There was no difference in baseline characteristics
between index and non-index cases with mean age (SD) of 35.2
(11.7) and 34.5 (12.1) years (p = 0.44), respectively, and proportion
of females being 40.9 and 35.2% (p= 0.10). Baseline character-
istics of all cases and controls are shown in Table 1. Mean BMI
was lower among cases, and the proportion with elevated serum
acute phase reactants was higher. Anti-retroviral treatment was
used by 10.7% of HIV infected.
Impaired glycaemia (IFG/IGT and diabetes) was found in
37.6% (95% CI: 34.2; 41.1) of cases and 21.4% (17.2; 26.1) of
controls. Similarly, levels of FBG and 2hBG were higher in the
case group (Table 2). The test for diabetes was done within 3 and 7
days of TB treatment initiation for 48 and 74%, respectively.
There were no differences in diabetes prevalence and blood
glucose levels in relation to time of testing.
In an unadjusted logistic regression model diabetes was
associated with TB (OR 2.2, 95% CI: 1.5; 3.4, p,0.001), and
there was no interaction with HIV (p= 0.99). After adjustment for
serum concentration of the acute phase reactant AGP and other
covariates the association between diabetes and TB increased to
an OR of 4.2, but only among HIV uninfected, whereas no
association was found among HIV infected (interaction, p= 0.01)
(Table 3). Adjustment with CRP instead of AGP produced similar
estimates. The results were not confounded by BMI nor waist
circumference (data not shown).
Discussion
This study shows that diabetes is a strong risk factor for
pulmonary TB. Furthermore, we found a high prevalence of
impaired glycaemia and diabetes among controls, randomly
selected from neighbours with the same sex and similar age as
index cases, but without evidence of TB. Considering that the
controls were generally poor, normal weight and young the
observed prevalence of diabetes of more than 9% was surprisingly
high. According to estimates by the International Diabetes
Foundation (IDF), the prevalence of diabetes in Tanzanian adults
between 20–79 years of age is 3.2% in 2010 [2]. Our data suggest
that this in an underestimate. This increase may be due to the on-
going nutritional transition, i.e. increased access to refined fat and
sugar combined with reduced physical activity [25].
The observed association between diabetes and pulmonary TB
is in accordance with reports from several other recent studies [26–
28]. A review of 13 observational studies, of which only one was
from a low-income country and none from Africa, found that
diabetes was associated with TB regardless of study design [26].
Based on the three cohort studies included in the review, the
summary estimate of the relative risk was 3.1 (95% CI: 2.3–4.3).
The results of the seven case-control studies included were
heterogeneous, with odds ratios ranging from 1.2 to 7.8. The
only data available from sub-Saharan Africa was from a hospital-
based study from Tanzania (1990) reporting a 6.5% prevalence of
diabetes among hospitalized TB patients, which was then
compared to a prevalence of 0.9% found in a separate community
survey [29].
Both cohort and case-control studies have inherent limitations.
In cohort studies, those found to have diabetes are generally under
treatment, which might reduce or eliminate any association, as the
effect of diabetes is likely to be mediated through hyperglycaemia.
In case-control studies, a positive association may be due to reverse
causality, i.e. stress-induced hyperglycaemia caused by TB. One
possible explanation for the elevation in blood glucose level in TB
is insulin resistance caused by severe infection [30]. In the current
study we adjusted for the acute phase response to reduce its effect
on blood glucose levels, and hence on the association between
impaired glycaemia and TB. This approach seemed to be
successful and should be used, in future case-control studies, to
reduce the problem of reverse causality.
To our knowledge this is the first study investigating the
association between diabetes and TB in a high HIV endemic area.
HIV affects half of the TB cases and one tenth of the non-TB
controls in this study population and is the strongest risk factor for
progression to active TB [13]. Interestingly, we found that after
adjustment for the acute phase response, HIV infection modified
the association between diabetes and TB. The increase in odds
ratio from two to four among the HIV uninfected could be due to
the adjustment for stress-induced hyperglycaemia. HIV infected
patients have impaired production of some acute phase reactants
[31], and the apparent lack of association between diabetes and
TB among the HIV infected after the adjustment for acute phase
reactants needs to be explored in future studies. Treatment with
Table 1. Background characteristics of 803 tuberculosis cases
and 350 controls (n = 1153)1.
Cases
(n=803)
Controls
(n =350) p
Female sex (%) 38.0 45.0 0.03
Age (y) 34.8 (11.9) 33.8 (12.0) 0.19
Ethnic group (%)
Msukuma tribe (%) 45.3 46.0 0.84
Other 54.7 54.0
Marital status
Single 27.1 25.4 ,0.001
Married/cohabiting 53.1 68.6
Separated/divorced/widow 19.7 6.1
Occupation (%)
Farmer/Fisherman 36.8 31.9 0.25
Businessman/Employed 36.4 40.5
Other 26.8 27.6
Religion (%)
Christian 73.7 78.5 0.02
Muslim 22.1 20.3
Other 4.2 1.2
BMI (kg/m2) 18.4 (2.7) 22.6 (4.1) ,0.001
HIV infection (%) 43.2 10.0 ,0.001
Acute phase response (elevated)
C-reactive protein .10 mg/L (%) 96.6 3.4 ,0.001
Orosomucoid .1.2 g/L (%) 97.3 2.7 ,0.001
1Data are mean (SD) or%.
doi:10.1371/journal.pone.0024215.t001
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antiretroviral treatment, which is known to cause metabolic
changes [32], did not affect the results (data not shown).
The association between diabetes and TB reported in this and
other case-control studies most likely reflect an elevated risk of TB
among diabetes patients. Poorly controlled diabetes may impair
the cell-mediated immune response and neutrophil function [9–
11,33], and hyperglycaemia alone may provide a better environ-
ment for bacterial growth and increased virulence of various
microorganisms [6].
The strength of our study is that TB was primarily diagnosed
based on culture result rather than microscopy, x-ray or clinical
symptoms. Furthermore, impaired glycaemia and diabetes were
based on FBG and OGTT according to the WHO epidemiolog-
ical definition [23], rather than FBG alone or register data. We
were therefore able to assess the relationship between impaired
glycaemia and diabetes, and pulmonary TB. Furthermore, by
including serum concentration of acute phase proteins in the
regression models we adjusted for stress-induced hyperglycaemia.
With adjustment, the magnitude of the association between IFG/
IGT and TB was sustained, whereas the association between
diabetes and TB increased, but only among the HIV uninfected.
Using FBG and 2hBG as continuous variables in the analysis
instead of categories may be more biologically correct, since cut-
offs used to define diabetes are arbitrary.
Table 2. Distribution of impaired glycaemia and diabetes and level of blood glucose based on 803 pulmonary tuberculosis cases
and 350 neighbourhood controls (n = 1153)1.
Cases (%) Controls (%) p
n=803 n=350
Glucose intolerance status
Normal glycaemia 62.4 (58.9;65.8) 78.6 (73.9;82.8) ,0.001
Impaired glycaemia
Isolated impaired fasting glucose (IFG) 8.0 (6.2;10.1) 6.9 (4.4;10.0)
Isolated impaired glucose tolerance (IGT) 6.0 (4.4;7.8) 2.6 (1.2;4.8)
Combined IFG/IGT 7.0 (5.3;9.0) 2.6 (1.2;4.8)
Diabetes 3 16.7 (14.2;19.4) 9.4 (6.6;13.0)
Blood glucose levels (mmol/L)
Fasting (n = 1153) 5.3 (1.6) 5.0 (1.0) ,0.001
2 hour post oral glucose tolerance test (n = 536) 2 7.7 (2.2) 7.1 (2.3) ,0.001
1Data are mean (SD) or% (95% CI).
2Oral glucose tolerance test performed if fasting blood glucose level was between 5.1–11.0 mmol/L.
3Diabetes diagnosis was based on either a FBG .6 mmol/L or a 2hBG .11 mmol/L.
doi:10.1371/journal.pone.0024215.t002
Table 3. Diabetes and all levels of IFG/IGT as predictors of pulmonary tuberculosis with odds ratio (OR) and 95% confidence
interval based on 803 pulmonary tuberculosis cases and 350 neighbourhood controls (N = 1153).
OR (95% C.I.) OR (95% C.I.) OR (95% C.I.)
Model 1 Model 2
Unadjusted
Adjusted for age, sex,
socio-demography 2 Model 1 + AGP 3
HIV negative (n = 770)
Glucose intolerance status 1
normal glucose tolerance ref. ref. ref.
IFG/IGT 2.26 (1.50;3.41) 2.34 (1.52;3.61) 2.65 (1.00;7.06)
diabetes 2.15 (1.35;3.42) 2.14 (1.32;3.46) 4.23 (1.54;11.57)
HIV positive (n = 382)
Glucose intolerance status 1
normal glucose tolerance ref. ref. ref.
IFG/IGT 2.16 (0.73;6.38) 1.78 (0.59;5.36) 3.54 (0.60;21.05)
diabetes 1.94 (0.65;5.75) 2.05 (0.68;6.19) 0.14 (0.01;1.81)
1Oral glucose tolerance test (OGTT) performed if fasting blood glucose level was between 5.1–11.0 mmol/L.
2Socio-demography includes religion, marital status and occupation.
3Interaction between diabetes and HIV, p = 0.01.
Abbreviations: IFG/IGT: all levels of impaired fasting glycaemia and impaired glucose tolerance; AGP: serum alpha-1-acid glycoprotein.
doi:10.1371/journal.pone.0024215.t003
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Conclusion
In view of the high prevalence of diabetes found in this study in
relatively young urban Tanzanian adults, an effect of diabetes on
the risk of TB is a major concern. The association is strongest
among HIV uninfected, whereas the effect needs to be further
investigated among HIV infected. Since diabetes is increasingly
widespread, even among the poor who are more likely exposed to
TB, it represents a serious threat to TB control. This underscores
the need for diabetes prevention and treatment programs in low-
income settings, and for integration of diabetes, HIV and TB
detection and case-management [34].
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